Antibe Therapeutics Inc ATE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATE is a good fit for your portfolio.
News
-
Antibe Announces Appointment of Receiver
-
Antibe Provides Update on CCAA Proceedings
-
Antibe Announces TSX Delisting Review
-
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
-
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
-
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order
-
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator
-
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Trading Information
- Previous Close Price
- CAD 0.26
- Day Range
- CAD 0.26–0.35
- 52-Week Range
- CAD 0.15–1.23
- Bid/Ask
- CAD 0.05 / CAD 0.05
- Market Cap
- CAD 15.64 Mil
- Volume/Avg
- 167,044 / 197,426
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.antibethera.com
Valuation
|
Metric
|
ATE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.99 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATE
|
|---|---|
Quick Ratio | 9.45 |
Current Ratio | 10.06 |
Interest Coverage | −2,490.63 |
Quick Ratio
ATE
Profitability
|
Metric
|
ATE
|
|---|---|
Return on Assets (Normalized) | −25.58% |
Return on Equity (Normalized) | −68.40% |
Return on Invested Capital (Normalized) | −53.05% |
Return on Assets
ATE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qsctkdzqgz | Fbv | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dmfkjry | Skwks | $108.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ltlckmrk | Hthbmvr | $105.3 Bil | |
MRNA
| Moderna Inc | Bjbtltmkm | Bdt | $47.0 Bil | |
ARGX
| argenx SE ADR | Vcpccbhp | Nkr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xzstkycfy | Jgpkj | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zrzlgvvbp | Flfyt | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fgktgqfcd | Cncpczj | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dwhqtdbdl | Zxcvwf | $12.6 Bil | |
INCY
| Incyte Corp | Dczsljss | Sbtmp | $12.0 Bil |